Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Last trade$13.71
Day change-$2.97 (-17.81%)
Day range$12.83 – $15.61
Volume3,661,688
Market cap$1.21B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.21B
Price / earnings
9.67×
Price / book
-23.51×
Price / sales
31.43×
EV / sales
33.28×
EV / EBITDA
-17.78×
Profitability
Earnings per share
$1.72
Return on assets
43.52%
Return on equity
-243.09%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-1.43×
Current ratio
1.95×
Quick ratio
1.94×
Cash ratio
0.02×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$68.73M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for OMER, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$28.53M
$9.89M
$0
$0
$0
$0
$0
$0
Cost of revenue
$798K
$587K
$0
$0
$0
$0
$0
$0
Gross profit
$27.73M
$9.31M
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$13.86M
$13.37M
$9.64M
$10.4M
$10.35M
$11.12M
$10.04M
$11.32M
Research and development
$13.8M
$13.36M
$19.45M
$16M
$22.01M
$23.85M
$23.32M
$24.08M
Total operating expenses
$27.66M
$26.73M
$29.08M
$26.39M
$32.35M
$34.97M
$33.36M
$35.41M
Operating income
$74K
-$17.42M
-$29.08M
-$26.39M
-$32.35M
-$34.97M
-$33.36M
-$35.41M
Interest expense
-$7.59M
-$5.89M
-$8.73M
$13.36M
-$15K
-$3.65M
-$3.18M
-$4.05M
Income before taxes
$6.67M
$51.31M
$81.9M
-$21.24M
-$25.89M
-$37.57M
-$34.24M
-$37.11M
Income taxes
$29K
$57K
$2.01M
$0
$0
$0
$2.31M
$0
Net income
$13.23M
$56.06M
$86.45M
-$30.92M
-$25.42M
-$33.46M
-$31.36M
-$32.23M
Net income attributable to common shareholders
$13.23M
$56.06M
$86.45M
-$30.92M
-$25.42M
-$33.46M
-$31.36M
-$32.23M
EBITDA
$267K
-$17.18M
-$28.85M
-$26.15M
-$32.15M
-$34.68M
-$33.05M
-$35.17M
Basic earnings per share
$0.18
$0.78
$1.22
-$0.47
-$0.43
-$0.58
-$0.54
-$0.56
Diluted earnings per share
$0.15
$0.62
$1.22
-$0.47
-$0.43
-$0.58
-$0.54
-$0.56
Recent news
Company coverage with links to the original publishers.
Omeros (OMER) reported quarterly earnings of $0.06 per share, beating consensus estimates by a loss of $0.05 and delivering a +220% earnings surprise. The company posted revenues of $35.93 million, surpassing estimates by 16.29%. Despite strong earnings performance, Omeros shares have underperformed the S&P 500 year-to-date, gaining 1.8% versus the market's 10.5% gain. The stock holds a Zacks Rank #2 (Buy) rating based on favorable estimate revisions.
Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation following the company's announcement on June 26, 2026, that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion on the marketing authorization application for narsoplimab for treating TA-TMA. The negative regulatory decision triggered a 19.12% stock price decline, falling $2.05 per share to $8.67.
Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation following the company's announcement of a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on its marketing authorization application for narsoplimab. The news triggered a 19.12% stock price decline on June 26, 2026.
The Portnoy Law Firm has initiated an investigation into possible securities fraud at Omeros Corporation following the European Medicines Agency's negative opinion on the company's narsoplimab marketing authorization application on June 26, 2026. The negative regulatory decision triggered a 19.12% stock price decline, dropping from $10.72 to $8.67 per share. The firm is seeking to file a class action lawsuit on behalf of affected investors.
Heartflow, an AI-driven diagnostic platform, shows strong 40% revenue growth but faces reimbursement headwinds and remains unprofitable. Omeros is transitioning to commercial stage with its newly approved drug Yartemlea, posting early Q1 2026 revenue of $9.89 million. The article recommends Omeros as the safer bet for 2026 despite trading at a premium, citing its transition to profitability versus Heartflow's expected positive free cash flow not until 2028.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.